HOYA combines defensive vision-care cash flows with EUV and AI-storage monopolies; despite a 31.3x–32.8x P/E, buybacks and secular growth support an attractive long-term upside case.
Overview
HOYA is a global medtech and deep-tech supplier whose advanced glass formulation and precision polishing create high switching costs in EUV mask blanks, HDD substrates and clinical vision products. Its hybrid structure pairs Life Care, approximately 60.5%–64% of revenue and relatively defensive, with Information Technology, approximately 36%–39.5% of revenue and a 55.1% segment operating margin. Q1 FY2026 revenue reached a record ¥255.7 billion, up 16.0% year over year or 7.0% in constant currency, while operating profit rose 24.0% to ¥82.4 billion and margin reached 32.2%. Net profit increased 28.1% to ¥65.8 billion, ROIC was 23.8%, and FCF was ¥62.9 billion. **The balance sheet is exceptionally strong**, with ¥555.5 billion of cash against ¥45.4 billion of debt. Management guides to H1 revenue of ¥521.0 billion and operating profit of ¥165.0 billion, while authorizing a ¥200 billion buyback and targeting a 40% dividend payout. **The central catalyst set is High-NA EUV, AI-driven nearline HDD growth and PENTAX divestiture.** At ¥24,965, valuation is demanding at 31.3x–32.8x trailing P/E and 20.2x EV/EBITDA, but the report’s base case reaches ¥39,060 in five years.